INKT MiNK Therapeutics
- 0.899
- -0.031-3.30%
- 0.871
- -0.028-3.15%
MiNK Therapeutics News
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
PDF Version NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
PDF Version MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activ
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
Buy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Moves
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2023 Earnings Conference
The following is a summary of the MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript:Financial Performance:MiNK Therapeutics ended the year with a cash balance of $3.4 million, boosted by
MiNK Therapeutics Is Maintained at Buy by HC Wainwright & Co.
MiNK Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9
HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics with a Buy and lowers the price target from $10 to $9.
Promising Clinical Progress and Market Potential for MiNK Therapeutics' AgenT-797 in Gastric Cancer Study
MiNK Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 900.22% HC Wainwright & Co. $10 → $9 Maintains Buy 08/10/2023 1011.36% HC Wainwright & Co. → $1
MiNK Therapeutics Q4 EPS $(0.16) Misses $(0.15) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 30.43 percent increase over losses of $
MiNK Therapeutics 4Q EPS 16c >INKT
MiNK Therapeutics 4Q EPS 16c >INKT
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to
MiNK Reports Fourth Quarter and Year-End 2023 Results
PDF Version Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape
Earnings Outlook For MiNK Therapeutics
MiNK Therapeutics (NASDAQ:INKT) is set to give its latest quarterly earnings report on Thursday, 2024-03-21. Here's what investors need to know before the announcement.Analysts estimate that MiNK Ther
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
PDF Version NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
PDF Version MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases ModelNEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT)
MiNK Therapeutics Strikes Convertible Note Deal With Agenus
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial With Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab
PDF Version Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer Center Trial is Supported by Stand Up To Cancer as Part of an Init
Analysis
Price Target
No Data
